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Aims: An increasing number of diagnostic and therapeutic medical devices are
available to help patients and physicians manage pelvic floor symptoms in
women. Many of these are presented at scientific conferences, and in the
absence of a gold standard for evaluation, marketing has become more
prominent than scientific evaluation. The goal of this study was to (a) provide
an overview of pelvic floor devices for women that have been presented at
recent annual meetings of leading scientific societies and (b) to summarize and
review the scientific evidence underpinning these devices.
Methods: Manual searches were performed of all abstracts presented in 2016
and 2017 at annual meetings of the International Continence Society, the
International Urogynecological Association, the European Association of
Urology, and the American Urological Association. The exhibition floor of
the 2017 International Continence Society was also searched. Subsequently,
literature searches of both the MEDLINE and Embase databases were
performed in November 2018 to identify original full‐text publications related
to the identified devices.
Results: We identified 11 devices from these sources, which were mainly used
for the control of urinary incontinence. Only seven of these pelvic floor devices
were covered by publications, with no full‐text records identified for the
remaining four devices.
Conclusions: Sample sizes were small and there was a lack of convincing
evidence for most devices. Despite this, many devices were available in the
market. Our findings indicate that the process for introducing these new devices
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
This study was presented as an ePoster and oral presentation at the
early career session of the annual meeting of the ICS held in
Philadelphia, 2018.
is in stark contrast with the strict requirements for introducing new drug
classes.
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1 | INTRODUCTION
Pelvic floor dysfunction refers to a variety of disorders or
diseases caused by impairment of the structural elements
of the pelvic floor and affects approximately a quarter of
adult women.1 The dysfunction can have a profoundly
negative effect on the quality of life,2,3 and can lead to
significant economic burdens.4,5 Guidelines often advo-
cate pelvic floor muscle training (PFMT), with or without
supervision, as a first‐line conservative treatment.6-8
Pelvic floor devices have therefore been developed and
are used as auxiliary aids for this training or as
alternative treatments.9-11 Given that some of these are
relatively new devices, no gold standard has been
developed against which they can be evaluated, with
development and marketing gaining a more prominent
role in their distribution and use than proper scientific
evaluation. In Europe and America, this is compounded
by the lack of a need for clinical data on effectiveness
before being granted marketing approval.12
Scientific meetings offer fantastic opportunities for
developers and scientists to present their devices and
work to professionals and the promotion of these devices
at meetings has grown. Therefore, we aimed to (a)
provide an overview of pelvic floor devices for women
that have recently been presented at the annual meetings
of leading scientific societies and (b) to review the
scientific evidence underpinning these devices.
2 | METHODS
2.1 | Search strategy
All abstracts presented at the annual meetings of the
International Continence Society (ICS), the International
Urogynecology Association (IUGA), the European Asso-
ciation of Urology (EAU), and the American Urological
Association (AUA) in 2016 and 2017 were manually
searched. Screening of titles and abstracts for inclusion
was conducted independently by two authors, while
another two authors attended the exhibition floor of the
2017 ICS annual meeting to identify devices. We did not
register this overview on the PROSPERO website,
because our aim was not to conduct a formal systematic
review.
2.2 | Study selection
We included devices designed to support the diagnosis
and/or treatment of any pelvic floor dysfunction in
women. Devices were excluded if they were (a) solely
intended for use in male subjects or (b) relied on a
physician for placement. Any disagreement on inclusion
or exclusion was resolved through discussion between
two researchers.
2.3 | Data extraction
Data extraction was independently performed by two
researchers. For all identified devices, we extracted the
following information from the manufacturers’ website
or brochures: type of device, target condition, and
availability. We then conducted literature searches of
both the MEDLINE and Embase databases in November
2018 to identify any scientific evidence concerning each
device. Rather than conducting a full search, we looked
for full‐text publications by entering the names of the
authors listed on the abstracts and the names of each
device. Original publications were obtained when possi-
ble, and the reference lists of each included article were
manually searched to find other relevant publications.
Finally, we collected full‐text publications, summarized
the evidence, and ranked them by study design, using the
pyramid of evidence.13 We did not assess the risk of bias
in the included studies because the number of rando-
mized controlled trials was expected to be low. Moreover,
a systematic assessment of quality was considered to be
beyond the scope of this study.
3 | RESULTS
3.1 | Device inclusion and study
identification
In total, we identified eleven eligible pelvic floor devices
(Figure 1). The literature search uncovered 10 original
full‐text publications, but these only referred to seven of
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the devices. No full‐text publications were available for
the remaining four devices. The details of the devices are
summarized in Table 1.
3.2 | Overview of the evidence for pelvic
floor devices
In the following text, we present the evidence available
from full‐text records for each device. The devices are
ranked by study design, according to the pyramid of
evidence.
3.2.1 | The MAPLe device
This is an electromyography‐electrode device that can
provide functional electronic stimulation. It was devel-
oped for diagnostic and therapeutic use in patients with
urinary incontinence (UI), fecal incontinence (FI),
overactive bladder (OAB), pelvic organ prolapse (POP),
and pelvic pain. One diagnostic study of 229 healthy
volunteers published in 2013 determined the device’s
reliability.14 The device was tested anally in men or
vaginally and anally in women among four groups of
volunteers. Test‐retest reliability was performed on a
random group of volunteers from all groups by calculat-
ing the intraclass correlation (ICC). Demographic data or
other information from these volunteers was not
described. The ICC was reported to be moderate
(0.5‐0.7) in six cases, good (0.7‐0.9) in fourteen cases,
and excellent (>0.9) in one case. However, no objective
comparisons of the measurements were made against
other commercially available probes because of reported
differences in shapes and sizes.
In 2017, a randomized controlled trial was performed
to assess the device for the treatment of OAB (n = 58).15
The effectiveness of biofeedback‐assisted pelvic muscle
FIGURE 1 Summary of abstract search, screening for relevant devices, and identification of corresponding full‐text records. AUA,
American Urological Association; EAU, European Association of Urology; ICS, International Continence Society; IUGA, International
Urogynecology Association
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therapy with the MAPLe (intervention group) was
compared against simple instructions on toilet behavior
and lifestyle (control group) in women with OAB. The
intervention group received weekly half‐hour sessions by
a pelvic floor therapist for nine consecutive weeks.
Compared with the control group, the authors found
significant improvements in the intervention group
across several outcome measures, including the Pelvic
Floor Inventories, the King’s Health Questionnaire,
24‐hour voiding diaries (urgency, P= .008), the daily
use of pads (P= .03), and 24‐hour pad tests.
3.2.2 | The Diveen device
This is an intravaginal, tampon‐like device designed to
treat stress UI by supporting the urethra and bladder
neck. We found a single prospective randomized parallel‐
group trial from 2012 that compared the effectiveness of 2
weeks’ treatment with an intravaginal tampon device
against no treatment for women with stress UI (n = 55),
using the Urinary Symptom Profile questionnaire.16 The
authors found a greater decrease in the primary outcome,
incontinence episode frequency, in the treated group
(mean −31.7%) than in the control group (mean −7.6%)
in the intention‐to‐treat analysis (P= .0023). Mean
symptom scores also decreased to a greater degree in
the treated group compared with the untreated group for
stress UI (P= .0043), OAB (P= .016), and dysuria
(P= .043). There were no statistically significant differ-
ences in pad‐test variations between both groups (P= .4).
3.2.3 | The Vibrance Kegel device
This is a T‐shaped biofeedback tool intended for use in
diagnosis and treatment of stress UI. The abstract
reported on a randomized controlled trial conducted
among 40 women with stress UI who were randomly
divided into two groups. This abstract contained no
updates from an earlier abstract presented in 201224 or a
full‐text article published in 2015.17 In this study, one
group received PFMT alone and the other group received
PFMT with biofeedback from the Vibrance Kegel device.
Both groups underwent 16 weeks of PFMT during which
they were treated individually by a physiotherapist in
monthly sessions lasting 20minutes. Assessments were
made at baseline, four, and 16 weeks, using the
Australian pelvic floor questionnaires and the modified
Oxford scales for pelvic floor muscle strength. Although
the number of patients with improved pelvic muscle
strength was significantly higher in the treatment group
TABLE 1 Summary of the identified devices: aims, usage, and available full‐text records
Device Condition
Diagnostic or
therapeutic Available for Presented at
Abstract
number Full‐text records
MAPLe UI, FI, OAB, POP
and pelvic pain
Both Caregivers ICS 2017 217 Reliability study14
and RCT15a
Diveen SUI Therapeutic Patients Exhibition
floor
– Phase III trial16
VPT/VKD SUI Therapeutic Patients ICS 2016 259 Pilot study17
IncoStress UI and POP Therapeutic Patients ICS 2016 411 Pilot study18







Diagnostic NA EAU 2017 1123 Diagnostic
reliability study20
Pericoach SUI, FI, and POP Therapeutic Patients IUGA 2017 171 Case studies21-23
Elitone SUI Therapeutic NA ICS 2017 467 No full text
Elvie SUI, SD, and PP
rehab





ICS 2017 887 No full text
IVPSD Unknown Diagnostic NA ICS 2016 414/538 No full text
Abbreviations: EAU, European Association of Urology; FI, fecal incontinence; ICS, International Continence Society; IUGA, International Urogynecology
Association; IVPSD, intravaginal pressure sensor device; MAPLe, Multiple Array Probe Leiden; NA, not yet available; OAB, overactive bladder; POP, pelvic
organ prolapse; PP rehab, postpartum rehabilitation; SD, sexual dysfunction; SUI, stress urinary incontinence; UI, urinary incontinence; VPT/VKD, vibrance
pelvic trainer/Vibrance Kegel device.
aThe reliability study was diagnostic and the randomised controlled trial (RCT) was for treatment.
bHorseback‐riding machine.
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after four (P= .027) and 16 weeks (P= .003) of continued
therapy, no significant differences were observed in
symptom scores or subjective cure rates at the end of
the study.
3.2.4 | The IncoStress device
This is another intravaginal tampon‐like device used to
treat UI and POP. An abstract of a randomized pilot study
that included 80 women were presented at ICS 2016 and
was subsequently published as a full‐text paper in 2018.18
Women with different types of UI were randomized to a
control group (receiving standard care and advice on
pelvic floor exercises and/or bladder retraining) or to an
intervention group (receiving usual care plus the use of
the IncoStress device) in a 1:2 ratio. Disease‐specific
outcomes were assessed and compared between groups at
3‐ or 6‐months follow‐up. Median Incontinence Quality
of Life scale score improved from 42.4 at baseline to 68.2
in pooled follow‐up data in the intervention group and
from 45.5 to 53.0 in the control group. Median Female
LUTS Questionnaire score in the intervention group
decreased from 14.5 to 12.5 and from 15.0 to 14.0 in the
control group. However, because of the mixed‐methods
feasibility study design, presented data were incomplete
and lacked formal statistical comparison, giving the
results little weight.
3.2.5 | The Magneto Stym device
This is a chair used for functional magnetic stimulation
in UI, FI, and postpartum rehabilitation. One preliminary
study of 10 men and 10 women with UI was published as
a full‐text paper in 2018.19 In this study, outcomes of
urodynamic tests and three life‐stress questionnaires
were compared pretreatment and posttreatment. The
authors reported significant improvements in cystometric
capacity, maximum urethral closure pressure, urethral
functional length, and pressure transmission ratio in
patients undergoing twice‐weekly treatment for 3 weeks.
Median values in symptom scores on all three ques-
tionnaires also showed significant reductions after 3
weeks (P< .01). Unfortunately, there was no control or
comparison group.
3.2.6 | The Peritron+ device
This handheld device is attached to urethral catheters to
measure intravesical pressure. A diagnostic validation
study of 10 patients with voiding dysfunction was
presented at ICS 2017 and published as a full‐text paper
in 2018.20 In this study, intravesical pressures were
measured at three different bladder volumes (50, 100, and
200mL) in supine and sitting positions and compared to
standard urodynamics in adult female patients with a
history of nonneurogenic (n = 9) or neurogenic (n = 1)
OAB. The device was judged to be comparable to
standard urodynamics when recorded intravesical pres-
sure differences between both methods were no larger
than 3 cmH2O. For all measurements, the absolute
difference in mean intravesical pressure values was
within this limit. No statistically significant difference
was found between measurements with standard urody-
namic equipment and the Peritron+ device. However,
there have been no clinical studies and it is not yet in the
market.
3.2.7 | The Pericoach device
This is another intravaginal biofeedback device that is
intended for the treatment of stress UI. We found three
different case reports that described the device’s benefits.
The first reported improved quality of life, with decreas-
ing scores on the Pelvic Floor Impact Questionnaire
Short Form 7 after use.21 The second reported decreased
POP symptoms based on the Pelvic Floor Disability Index
and POP‐Distress Inventory scores.22 The last‐reported
improvement in the Pelvic Floor Distress Inventory Short
20.23 Abstracts were also presented in 2017, included one
reporting a randomized controlled trial with 47 women
and one reporting a trial with 51 women. In both
abstracts, the efficacy of the device was evaluated over 20
weeks by comparing a control group who performed
PFMT to an intervention group performing exercises
using the device. Both abstracts reported improvements
in different questionnaires. However, it was unclear
whether these were two separate trials or two reports of
the same ongoing trial. No full‐text records of these trials
were available.
3.2.8 | The Elitone device
This is a surface electrode device intended to treat stress
UI that is purported to work through electrical muscle
stimulation of the perineal region. An assessment of
device usability was presented in an abstract at ICS 2017.
Seven different waveforms of electrical stimulation with
gradually increasing voltage were tested in eight women.
The participants were asked to describe the first
perception of initial muscle stimulation, the most
comfortable level of pelvic floor muscle contraction,
and the most comfortable waveform. Details of these
were presented in the results, but we found no full‐text
publications. This device was not available for sale at the
time of writing.
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3.2.9 | The Elvie device
This intravaginal biofeedback device is intended for
postpartum rehabilitation, stress UI, and sexual dysfunc-
tion. One abstract used data from a cohort of 1182 female
users to assess the benefits of the device for research use.
General conclusions were drawn from these data, such as
the observation that childbirth significantly impacted
pelvic floor strength and that this effect was attenuated
with increasing age. In another abstract, authors reported
a positive impact of the device on the frequency of PFMT
based on data from a web survey completed by 417 users.
To date, no full‐text publications are available.
3.2.10 | The Panasonic EU‐JC70 device
This is a horseback‐riding fitness machine that aims to
treat stress UI. Details of the device and its efficacy in a
study of 24 women were presented in an abstract at ICS
2017. The authors reported that there were significant
increases in vaginal squeeze pressure, as assessed by
perineometer, and improvements in symptom scores
after thirteen weeks of training in the intervention group
compared to a control group. However, we found no full‐
text publications.
3.2.11 | The IVPSD
At the ICS 2016 meeting, an IVPSD (intravaginal pressure‐
sensing device) was presented in two separate abstracts.
These abstracts describe bench and in vivo testing of this
device in four women. The authors report the reliability
and repeatability of the device for measuring vaginal
pressure profiles at rest and during exercise. Again,
however, there have been no full‐text publications and
the device has not been made commercially available.
4 | DISCUSSION
In this study, we aimed to give an overview of the
evidence base for pelvic floor devices for women, as
presented at scientific meetings in 2016 and 2017. Eleven
devices, mainly intended for the treatment of UI, were
presented at these meetings. Although we found full‐text
publications for seven devices, our searches yielded no
such evidence for four of the devices.
The MAPLe device was supported with data from
peer‐reviewed journals. By contrast, the evidence for all
other devices was, at best, limited. These findings are
consistent with those of a systematic review from 2011,
reporting that adding (bio)feedback to PFMT could have
a beneficial effect in women with UI. However, the
authors reported that risk of bias was high in most
included trials and that further research was necessary.11
A more recent systematic review on mechanical devices
for UI in women found little to no evidence of
effectiveness over no treatment,9 supporting our findings
that only a limited evidence base is provided for new
pelvic floor devices.
Interestingly, despite there only being pilot studies or
case studies in most cases, seven devices were commer-
cially available for patients or caregivers at the time of
writing. An explanation for this scarcity of evidence is
that the requirements for medical devices tend to focus
on safety rather than effectiveness. In Europe, medical
devices can be marketed after receiving a Conformité
Européenne (CE) mark, with different performance and
reliability testing standards applied depending on the
regulatory class assigned to a device. Similarly, in the
United States, the Food and Drug Administration (FDA)
applies different levels of control when assessing the
safety and effectiveness of a new device depending on the
regulatory class. If a new device is shown to be
substantially equivalent to an existing legally marketed
device, clinical tests of safety and effectiveness are
usually unnecessary.12 Although the FDA provides
thorough guidance for medical devices intended to treat
UI,25 these are nonbinding. Given that many perine-
ometers, electrical continence devices, and other vaginal
devices are readily available in the market, new pelvic
floor devices can receive FDA‐approval or clearance by
demonstrating substantial equivalence.
4.1 | Strengths and limitations
To the best of our knowledge, this is the first study to
have explored the evidence base for medical devices
presented at scientific meetings. However, the overview
was incomplete because we limited the search to the
scientific meetings of only four scientific societies in 2016
and 2017. We also acknowledge that we may have failed
to identify publications submitted to scientific journals
not covered by our searches, although we did try to
explore the gray literature by extracting data from the
manufacturers’ websites. Also, we are unfortunately
unaware of the number of users for each device and
whether devices are reimbursed in different countries.
Costs, either for patients or for the health care system,
should ideally also be taken into account when applying
these devices. Another weakness is the lack of a clear
definition of what constitutes a pelvic floor device.
Although eligible devices were discussed among the
authors, no firm definition was agreed upon and the
decisions were subjective. Nevertheless, this approach did
allow us to perform manual searches of abstract
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databases without being restricted to specific keywords.
The major differences in device types, target conditions,
and study designs meant that we could only rank devices
by the level of evidence and could not provide
comparative assessments. Moreover, there are no clear
guidelines or gold standards for the evaluation of such
devices; in future research, we must ensure that both are
available to facilitate clinically relevant assessments of
evidence quality. The lack of structured assessment of
potential bias may also be considered a weakness, but
given that our main finding was that there is a paucity of
evidence in peer‐reviewed publications, adding such
assessment would probably have added little.
5 | CONCLUSION
Despite the clear limitations of this study, we showed that
there is a lack of evidence for most of the devices presented
in abstracts at scientific meetings. Nearly all devices
presented in this overview lacked future supporting data
from full validation or clinical studies. We found that our
work, therefore, raised several important questions that went
beyond the scope of the overview, and to which we are
unable to offer meaningful answers. For example, do the CE
and FDA systems offer routes by which medical companies
can circumvent the rigor of peer review? Are abstract
presentations that receive no further formal follow‐up a way
of gaining a degree of undeserved scientific validity, or are
they simply an effective way to present data that might not
otherwise be published? Although performing trials and
publishing the results in peer‐reviewed journals may be
costly, time‐consuming, and may fail to deliver the desired
outcomes, only by thorough evaluation can we ensure the
delivery of good clinical care. We believe that overviews such
as this offer a means by which the wider scientific
community can monitor the scientific merit of devices. In
the long term, however, better regulatory mechanisms are
needed.
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